Lars Bullinger, MD, received his medical degree from Heidelberg Medical School in Heidelberg, Germany. He also attended the Baylor College of Medicine in Houston, TX, and Duke University in Durham, NC, in 1998. In 2008, he completed a residency in internal medicine at the University of Ulm in Ulm, Germany, after which he became an Assistant Professor. In 2016, Prof. Bullinger became an Associate Professor of Personalized Medicine at the University of Ulm.
Prof. Bullinger has served the Charité University of Medicine in Berlin, Germany, as a Professor of Hematology/Oncology since 2017, and is currently the Director of the Department of Hematology, Oncology and Tumorimmunology. Prof. Bullinger is also a member of the HARMONY alliance (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology).
Speaking on molecular classification and precision medicine in AML
Prof. Bullinger’s works is focused on translational research and integrative analyses of next-generation sequencing and “omics” data. Prof Bullinger investigates molecular tumor classification with an aim of developing and improving precision medicine approaches, in particular for acute myeloid leukemia (AML).
Prof. Bullinger is also leading a HARMONY Research Project which utilizes big data to revise and improve treatment strategies in AML, by determining how certain genomic interactions influence the progression of disease.